A Phase 2 Study of Pembrolizumab Combined with Chemoradiotherapy as Initial Treatment for Anaplastic Thyroid Cancer
- 14 November 2019
- journal article
- research article
- Published by SAGE Publications in Thyroid®
- Vol. 29 (11) , 1615-1622
Abstract
Background: Anaplastic thyroid cancer (ATC) has poor prognosis with median overall survival (OS) of ∼6 months. We previously reported high PD-1/PDL-1 staining in ATC, raising the possibility of the productive application of the immunotherapeutic pembrolizumab. However, having found pembrolizumab to anecdotally have limited single-agent activity in ATC, we sought to alternatively define whether pembrolizumab might synergistically combine with chemoradiotherapy as initial ATC therapy. Methods: An investigator-initiated therapeutic phase 2 trial of pembrolizumab, 200 mg intravenously (IV) every 3 weeks, combined with chemoradiotherapy (docetaxel/doxorubicin, 20 mg/m 2 each IV weekly plus volumetric modulated arc therapy) was initiated as frontline therapy (with or without surgery) in ATC to assess efficacy and toxicities. Six-month OS was selected as the primary endpoint using a Simon's optimal design with interim analysis (targeting accrual of 25 patients; Cohort A: prior resection, Cohort B: no resection). Based on a prior patient cohort-treated similarly, but without pembrolizumab, the design was such that, if 6-month true survival is 75%, the probability of declaring the approach worthy of further pursuit would be 91%. Results: Three patients were enrolled, two with rapidly enlarging unresectable neck masses. Early tumor responses were favorable in all three, and all three satisfactorily completed: intended radiotherapy, preceding and radiotherapy-concurrent pembrolizumab, and concurrent chemoradiotherapy. However, all three patients died <6 months following therapy initiation—one from pulmonary metastases and two from otherwise unexpected fatal pulmonary complications occurring subsequent to chemoradiotherapy completion—prompting study closure. Conclusions: Although initially tolerated and effective in terms of locoregional disease control, disappointing survival outcomes compared with historical controls raise uncertainty that the piloted approach merits further pursuit in ATC.Keywords
This publication has 24 references indexed in Scilit:
- Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid CancerThe Journal of Clinical Endocrinology & Metabolism, 2016
- Genomic Alterations of Anaplastic Thyroid Carcinoma Detected by Targeted Massive Parallel Sequencing in a
BRAF
V600E
Mutation-Prevalent AreaThyroid®, 2016
- Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancersJournal of Clinical Investigation, 2016
- Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencingHuman Molecular Genetics, 2015
- Anaplastic Thyroid Carcinoma: A 25-year Single-Institution ExperienceAnnals of Surgical Oncology, 2014
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in MelanomaNew England Journal of Medicine, 2013
- Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancerEndocrine-Related Cancer, 2008
- Anaplastic thyroid cancer in British Columbia 1985–1999: a population-based studyClinical Oncology, 2005
- Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2004
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989